BI 9564 (CAS 1883429-22-8)
Alternate Names:
BI9564 4-(4-((dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one BI-9564 CHEMBL3823101
CAS Number:
1883429-22-8
Molecular Weight:
353.40
Molecular Formula:
C20H23N3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
BI 9564 (CAS 1883429-22-8) References
- BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors. | Krämer, KF., et al. 2017. Int J Mol Sci. 18: PMID: 28714904
- A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells. | Gatchalian, J., et al. 2018. Nat Commun. 9: 5139. PMID: 30510198
- GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer. | Bevill, SM., et al. 2019. Mol Cancer Res. 17: 1503-1518. PMID: 31000582
- Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains. | Karim, RM., et al. 2020. J Med Chem. 63: 3227-3237. PMID: 32091206
- BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4. | Ahmed, NS., et al. 2022. Proc Natl Acad Sci U S A. 119: PMID: 34983841
- Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights. | Müller, MR., et al. 2022. Clin Epigenetics. 14: 5. PMID: 34996497
- BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5. | Wang, Y., et al. 2020. Transl Cancer Res. 9: 3354-3366. PMID: 35117701
- H3K27ac mediated SS18/BAFs relocation regulates JUN induced pluripotent-somatic transition. | Lin, R., et al. 2022. Cell Biosci. 12: 89. PMID: 35710570
- Reevaluation of bromodomain ligands targeting BAZ2A. | Cazzanelli, G., et al. 2023. Protein Sci. 32: e4752. PMID: 37574751
- DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance. | Schröder, M., et al. 2024. Nat Commun. 15: 275. PMID: 38177131
Inhibitor of:
BAZ2A, BC032203, Bet1L, BRDT, Brg-1, CHD1L, HNF-1β, and Swi3.Activator of:
PHF19.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BI 9564, 1 mg | sc-507350 | 1 mg | $83.00 |